Lonza to expand capacity at manufacturing sites in Switzerland


Lonza’s investment in its Stein and Basel facilities in Switzerland aims to expand all of its drug development and manufacturing services.

Lonza announced on September 22, 2021 that it will invest in additional drug manufacturing capacity at its Stein site in Switzerland. The investment will finance an additional flexible aseptic filling line for the clinical supply of pharmaceuticals.

The new line will support the filling and processing of liquid and lyophilized vials as well as pre-filled cartridges and syringes. This line will allow Lonza to process a variety of modalities, including monoclonal antibodies, bioconjugates, viral vectors and various other gene therapy products. According to a press release from the company, the filling line will implement advanced robotic technology and implement innovative freeze-drying technology with an air cooling system. Scheduled for completion in 2023, the facility will create more than 70 new jobs at the Stein site.

Along with increasing global pharmaceutical capacity, Lonza will expand its pharmaceutical service footprint for parenteral dosage forms at its Basel location. This will increase the process development and characterization capabilities offered at the site, supporting both early and late clinical stage pharmaceutical development. It should be operational in 2024.

“The expansion of pharmaceutical capacities in Switzerland allows our customers to access a flexible and integrated offering including development, testing and manufacturing services for mammalian, microbial, bioconjugate, cell and gene therapy products and small molecules, ”said Jean-Christophe Hyvert. , president of biologics and Lonza cells and genes, in a press release. “Improving our global pharmaceutical capacity underscores Lonza’s continued commitment to providing our customers with an end-to-end solution across a variety of modalities and scales. “

“Our pharmaceutical service offering in Basel is a world-class capability and represents a center of excellence for Lonza’s global pharmaceuticals network,” said Peter Droc, head of pharmaceutical services at Lonza, in a statement. Press release. “Along with the investment in the filling line at Stein, by expanding the footprint and capabilities of our pharmaceutical services departments, we are able to meet customer demand for integrated solutions. “

Source: Lonza


Comments are closed.